These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21675837)

  • 21. Diagnosing malignant pleural effusions: how do we compare?
    Lim MH; Garrettc J; Mowlem L; Yap E
    N Z Med J; 2013 Aug; 126(1381):42-8. PubMed ID: 24150264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic value of tumor markers in lung adenocarcinoma-associated cytologically negative pleural effusions.
    Hsieh TC; Huang WW; Lai CL; Tsao SM; Su CC
    Cancer Cytopathol; 2013 Sep; 121(9):483-8. PubMed ID: 23408492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions.
    Porcel JM; Salud A; Vives M; Esquerda A; Rodríguez-Panadero F
    Clin Biochem; 2005 Nov; 38(11):1031-3. PubMed ID: 15925354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
    Afify A; Lynne LC; Howell L
    Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Multicancer Malignant Pleural Effusion Diagnostic Test Using Hexokinase 2 and Single-Cell Sequencing.
    Chen J; Yang Y; Wang Z; Shen X; Zhang Z; Wang C; Xu H; Shi Q
    Clin Chem; 2022 May; 68(5):680-690. PubMed ID: 35142335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. hTERT gene amplification and clinical significance in pleural effusions of patients with lung cancer.
    Cha N; Li XY; Zhao YJ; Wang EH; Wu GP
    Clin Lung Cancer; 2012 Nov; 13(6):494-9. PubMed ID: 22464057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic profiling of putative breast cancer stem cells from malignant pleural effusions.
    Tiran V; Stanzer S; Heitzer E; Meilinger M; Rossmann C; Lax S; Tsybrovskyy O; Dandachi N; Balic M
    PLoS One; 2017; 12(4):e0175223. PubMed ID: 28423035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic yield of closed pleural brushing.
    Aksoy E; Ataç G; Sevim T; Güngör G; Törün T; Maden E; Tahaoğlu K
    Tuberk Toraks; 2005; 53(3):238-44. PubMed ID: 16258882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of two fluorescence in situ hybridization (FISH) probes for diagnosing malignant pleural effusions.
    Rosolen DC; Kulikowski LD; Bottura G; Nascimento AM; Acencio M; Teixeira L; Vargas FS; Sales RK; Antonangelo L
    Lung Cancer; 2013 Jun; 80(3):284-8. PubMed ID: 23453645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Label-Free Quantitative Proteomics Identifies Novel Biomarkers for Distinguishing Tuberculosis Pleural Effusion from Malignant Pleural Effusion.
    Pan L; Zhang X; Jia H; Huang M; Liu F; Wang J; Du B; Wei R; Sun Q; Xing A; Li Q; Zhang Z
    Proteomics Clin Appl; 2020 Jan; 14(1):e1900001. PubMed ID: 31715074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted proteomics pipeline reveals potential biomarkers for the diagnosis of metastatic lung cancer in pleural effusion.
    Chen CD; Wang CL; Yu CJ; Chien KY; Chen YT; Chen MC; Chang YS; Wu CC; Yu JS
    J Proteome Res; 2014 Jun; 13(6):2818-29. PubMed ID: 24787432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
    Stathopoulos GT; Psallidas I; Moustaki A; Moschos C; Kollintza A; Karabela S; Porfyridis I; Vassiliou S; Karatza M; Zhou Z; Joo M; Blackwell TS; Roussos C; Graf D; Kalomenidis I
    J Natl Cancer Inst; 2008 Oct; 100(20):1464-76. PubMed ID: 18840818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The evolving role of interventional pulmonary in the interdisciplinary approach to the staging and management of lung cancer. Part III: diagnosis and management of malignant pleural effusions.
    Yoneda KY; Mathur PN; Gasparini S
    Clin Lung Cancer; 2007 Nov; 8(9):535-47. PubMed ID: 18186958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An investigation of adequate volume for the diagnosis of malignancy in pleural fluids.
    Thomas SC; Davidson LR; McKean ME
    Cytopathology; 2011 Jun; 22(3):179-83. PubMed ID: 20636404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic and prognostic implications of pleural adhesions in malignant effusions.
    Bielsa S; Martín-Juan J; Porcel JM; Rodríguez-Panadero F
    J Thorac Oncol; 2008 Nov; 3(11):1251-6. PubMed ID: 18978559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diagnostic value of DNA, RNA and proliferating cell nuclear antigen examination in malignant pleural effusions by flow cytometry].
    Wang LX; Chen WX; Wu J; Chen SX; Huang XY; Chen YF
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Dec; 29(12):804-7. PubMed ID: 17327081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of cytology, fluorescence in situ hybridization for aneuploidy, and reverse-transcriptase polymerase chain reaction for human mammaglobin/mammaglobin B expression improves diagnosis of malignant effusions.
    Fiegl M; Haun M; Massoner A; Krugmann J; Müller-Holzner E; Hack R; Hilbe W; Marth C; Duba HC; Gastl G; Grünewald K
    J Clin Oncol; 2004 Feb; 22(3):474-83. PubMed ID: 14752070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
    Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
    Cancer; 1996 Aug; 78(4):736-40. PubMed ID: 8756365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etiology and prognostic significance of massive pleural effusions.
    Jiménez D; Díaz G; Gil D; Cicero A; Pérez-Rodríguez E; Sueiro A; Light RW
    Respir Med; 2005 Sep; 99(9):1183-7. PubMed ID: 16085221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology.
    Findeis-Hosey JJ; Xu H
    Hum Pathol; 2011 Mar; 42(3):303-14. PubMed ID: 20970161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.